1. Home
  2. JMM vs LPCN Comparison

JMM vs LPCN Comparison

Compare JMM & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Multi-Market Income Fund (MA)

JMM

Nuveen Multi-Market Income Fund (MA)

HOLD

Current Price

$5.78

Market Cap

58.5M

Sector

Finance

ML Signal

HOLD

Logo Lipocine Inc.

LPCN

Lipocine Inc.

HOLD

Current Price

$6.92

Market Cap

61.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JMM
LPCN
Founded
1988
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.5M
61.8M
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
JMM
LPCN
Price
$5.78
$6.92
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$15.00
AVG Volume (30 Days)
17.1K
123.9K
Earning Date
01-01-0001
03-10-2026
Dividend Yield
5.44%
N/A
EPS Growth
N/A
46.18
EPS
N/A
N/A
Revenue
N/A
$1,976,677.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$74.43
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.68
$2.52
52 Week High
$6.52
$12.37

Technical Indicators

Market Signals
Indicator
JMM
LPCN
Relative Strength Index (RSI) 30.27 36.50
Support Level $5.77 $2.87
Resistance Level $6.39 $10.68
Average True Range (ATR) 0.04 0.67
MACD -0.02 -0.17
Stochastic Oscillator 10.81 2.11

Price Performance

Historical Comparison
JMM
LPCN

About JMM Nuveen Multi-Market Income Fund (MA)

Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities, including, but not limited to, residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.

About LPCN Lipocine Inc.

Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Share on Social Networks: